Biomedical engineering — US PTAB Patent Cases
6 decisions indexed
Page 1 of 1 · 6 total
ZEPP HEALTH CORPORATION v.Worcester Polytechnic Institute
Zepp Health and Worcester Polytechnic Institute have settled their IPR dispute over a respiratory‑rate patent, filing a joint motion to terminate the proceeding before institution.
Axion Biosystems, Inc. v.Agilent Technologies, Inc.
Axion Biosystems successfully navigated the Institution Decision phase in its IPR against Agilent Technologies, leading to the trial of key claims. The Board declined to deny institution, allowing the dispute over cell monitoring and impedance analysis technology to proceed to litigation.
Embody, Inc. et al. v.LifeNet Health
Embody and Zimmer Biomet have filed an IPR petition seeking cancellation of claims 1‑8 of LifeNet Health’s 11,318,227 patent covering electrospun collagen scaffolds. They argue obviousness and anticipation based on Huang2, Kuo, and Lee, and request institution of the review.
Embody, Inc. et al. v.LifeNet Health
Embody and Zimmer Biomet have filed an IPR seeking cancellation of all 12 claims of LifeNet Health’s 2018 scaffold patent, arguing anticipation by earlier academic publications and obviousness. The petition emphasizes strong discretionary factors favoring institution.
Embody, Inc. et al. v.LifeNet Health
Embody, Inc. challenged LifeNet Health's tissue engineering patent (11318227) based on anticipation and obviousness. The PTAB instituted trial on all eight claims after finding merit in the petitioner’s arguments regarding fiber alignment and FFT analysis.
Embody, Inc. et al. v.LifeNet Health
Embody and Zimmer Biomet successfully secured institution in this IPR against LifeNet Health's '223 patent. The Board found a reasonable likelihood that claims related to collagen scaffolds with specific FFT analysis characteristics are unpatentable over prior art references like Huang2 and Lee.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.